ReviewSignal transduction and targeted therapy2026
Vascular calcification: pathogenic mechanisms, signaling crosstalk and translational therapeutics.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular calcification (VC) is a multifactorial pathological process characterized by ectopic deposition of hydroxyapatite in the arterial wall, which is closely associated with increased cardiovascular morbidity and mortality. This review provides a comprehensive synthesis of current insights into the pathogenesis of VC, emphasizing its nature as a dynamically regulated process driven by intricate crosstalk among diverse molecular mechanisms, signaling cascades, and pathological pathways. Under specific pathological stimuli, this intricate regulatory network disrupts the homeostatic balance between pro-calcific and anti-calcific mechanisms. Key drivers of VC include the phenotypic transformation of vascular smooth muscle cells (VSMCs), endothelial-to-mesenchymal transition (EndMT), inflammation, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and various forms of programmed cell death. The transcription factor RUNX2 serves as a central regulator, integrating signals from pathways such as WNT/β-catenin, BMP/Smad, PI3K/AKT, MAPK, AMPK, NF-κB, Notch, and Rho/ROCK. Furthermore, emerging evidence highlights the critical regulatory roles of epigenetic mechanisms, including posttranslational modifications (PTMs) and noncoding RNAs (lncRNAs, miRNAs, circRNAs). Given the complexity of VC, we critically evaluate the efficacy and safety of various pharmacological interventions from clinical trials, including bisphosphonates (BPs), calcimimetics, phosphate binders, dipeptidyl peptidase-4 inhibitor (DPP4i), SNF472, sodium-glucose cotransporter 2 inhibitors (SGLT2i), statins, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), sodium thiosulfate, and vitamins K and D, while also discussing potential endogenous molecules and natural compounds. A deep understanding of these interconnected molecular networks is essential for developing precision therapies to mitigate VC and VC-related cardiovascular complications.
Indexed as
Identifiers
42823400What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.